NANT 2004-03: A Phase I Study of Intravenous (Emulsion) Fenretinide in Children with Recurrent or Resistant Neuroblastoma

What is the purpose of this study?

This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.

Conditions

  • Cancer - Neuroblastoma
  • Medications

What is involved?

This is a multicenter study.

Patients receive fenretinide IV continuously over 120 hours on days 0-4. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for pharmacokinetic analysis by high performance liquid chromatography. After completion of study treatment, patients are followed periodically.

Who should I contact for more information?

Cincinnati Children’s Hospital Medical Center
Cancer and Blood Diseases Institute
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799
cancer@cchmc.org

Where can I find additional information?